Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
05.06. | Kiniksa sets Phase 2/3 trial for heart drug KPL-387 | 2 | Investing.com | ||
05.06. | Kiniksa Pharmaceuticals, Ltd.: Kiniksa Pharmaceuticals Announces Trial Design of Planned Phase 2/3 Clinical Trial of KPL-387 in Recurrent Pericarditis | 225 | GlobeNewswire (Europe) | - KPL-387 Phase 2/3 trial on track to initiate in mid-2025; Phase 2 data expected in 2H 2026 -- KPL-387 Phase 1 single ascending dose data support profile for monthly dosing -- Presentation and webcast... ► Artikel lesen | |
03.06. | Kiniksa Pharmaceuticals International, plc - 8-K, Current Report | 1 | SEC Filings | ||
30.04. | Kiniksa Pharmaceuticals, Ltd.: Kiniksa Pharmaceuticals Announces GRAMMY Award-Winning Country Star, Carly Pearce, Joins the Life DisRPted Campaign, Adding to Voices Advocating for Awareness of Recurrent Pericarditis | 1 | GlobeNewswire (USA) | ||
KINIKSA PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
29.04. | Kiniksa Pharmaceuticals International, plc - 10-Q, Quarterly Report | - | SEC Filings | ||
29.04. | Kiniksa raises ARCALYST 2025 revenue guidance to $605M amid strong Q1 performance | 3 | Seeking Alpha | ||
29.04. | Kiniksa Pharmaceuticals International, plc GAAP EPS of $0.11 beats by $0.09, revenue of $137.7M beats by $5.99M | 1 | Seeking Alpha | ||
29.04. | Kiniksa Pharmaceuticals, Ltd.: Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution | 353 | GlobeNewswire (Europe) | - ARCALYST® (rilonacept) Q1 2025 net product revenue of $137.8 million, representing 75% year-over-year growth -- ARCALYST 2025 expected net product revenue increased to $590 - $605 million -- KPL-387... ► Artikel lesen | |
28.04. | Examining the Future: Kiniksa Pharmaceuticals' Earnings Outlook | 1 | Benzinga.com | ||
24.04. | Kiniksa Pharmaceuticals, Ltd.: Kiniksa Pharmaceuticals to Report First Quarter 2025 Financial Results on April 29, 2025 | 1 | GlobeNewswire (USA) | ||
23.04. | Kiniksa Pharmaceuticals International, plc - 8-K, Current Report | 1 | SEC Filings | ||
06.03. | Kiniksa Pharmaceuticals Stock Is Attractive From Valuation Perspective-JP Morgan Analyst | 5 | Benzinga.com | ||
25.02. | Kiniksa Pharmaceuticals International, plc - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
25.02. | Kiniksa Pharmaceuticals International, plc - 10-K, Annual Report | - | SEC Filings | ||
25.02. | Kiniksa adds to Sjögren's exodus with trial termination, axes AstraZeneca asset | 5 | FierceBiotech | ||
25.02. | Kiniksa to launch Phase 2/3 trial for heart drug KPL-387 | 2 | Investing.com | ||
25.02. | Kiniksa Pharmaceuticals, Ltd. Q4 Earnings Summary | - | RTTNews | ||
25.02. | Kiniksa startet Phase-2/3-Studie für Herzmedikament KPL-387 | - | Investing.com Deutsch | ||
25.02. | Kiniksa Pharmaceuticals, Ltd.: Kiniksa Pharmaceuticals Announces Development of KPL-387 in Recurrent Pericarditis and Updates Corporate Strategy | 357 | GlobeNewswire (Europe) | - Kiniksa plans to initiate a Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis in mid-2025 - - KPL-387 Phase 1 single ascending dose data support potential monthly dosing - - Kiniksa... ► Artikel lesen | |
25.02. | Kiniksa Pharmaceuticals, Ltd.: Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Portfolio Execution | 348 | GlobeNewswire (Europe) | - ARCALYST® (rilonacept) Q4 2024 and full year 2024 net product revenue of $122.5 million and $417.0 million, respectively -- ARCALYST 2025 net product revenue expected to be $560 - $580 million --... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 90,70 | -0,60 % | Die nächste Cashcow? Schnelle Prozente mit NetraMark, Moderna, BioNTech | Erinnern Sie sich noch an den Impfstoff-Wettlauf in der Corona-Zeit? Damals bestimmte das Duell zwischen BioNTech und Curevac auch das Geschehen an der Börse. Anleger der ersten Stunde machten schnell... ► Artikel lesen | |
BB BIOTECH | 32,500 | +0,46 % | Zwischen Aufbruch und Wandel: Biotech im Check: Wo liegen die Chancen? - BB Biotech: Diversifizierung innerhalb einer Aktie | Steht die Biotech-Branche vor einem strukturellen Wandel? Enormes Innovationspotenzial und gute Voraussetzungen für M&A-Aktivitäten könnten Schwung in den Sektor bringen. Wie geht es eigentlich der... ► Artikel lesen | |
CUREVAC | 4,560 | -0,91 % | EQS-News: CureVac Announces Voting Results of General Meeting | Emittent / Herausgeber: CureVac
/ Schlagwort(e): Hauptversammlung
CureVac Announces Voting Results of General Meeting
24.06.2025 / 22:09 CET/CEST
Für den Inhalt der... ► Artikel lesen | |
MODERNA | 23,305 | +0,17 % | Laboratorios Rovi: FDA approves Moderna vaccine for RSV in adults aged 18 to 59 | ||
AMGEN | 237,00 | +0,11 % | Amgen-Aktie mit Kursverlusten (237,1233 €) | An der US-amerikanischen Börse notiert die Aktie von Amgen derzeit etwas leichter. Der jüngste Kurs betrug 277,19 US-Dollar. An der Börse liegt die Aktie von Amgen zur Stunde im Minus. Das Wertpapier... ► Artikel lesen | |
NOVAVAX | 5,424 | -0,40 % | Novavax Aktie: Sondermeldung sorgt für starke Verunsicherung. Das ist der Grund und so müssen Anleger heute handeln! | ||
BIOGEN | 108,05 | +0,32 % | Biogen Inc.: New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMA | New analyses from DEVOTE Part C further characterize the improvements in motor function in participants with SMA who transitioned to the investigational higher dose regimen of nusinersen from 12 mg... ► Artikel lesen | |
REGENERON PHARMACEUTICALS | 444,00 | -0,22 % | Bayer, Regeneron get EU nod for Eylea's label extension | ||
MAINZ BIOMED | 2,775 | -100,00 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed erhält staatliche Förderung für die Entwicklung seines innovativen Tests zur Früherkennung von Bauchspeicheldrüsenkrebs | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Sonstiges
Mainz Biomed erhält staatliche Förderung für die Entwicklung seines innovativen Tests zur Früherkennung von... ► Artikel lesen | |
VIKING THERAPEUTICS | 22,700 | +0,13 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Initiation of Phase 3 Obesity Clinical Program with GLP-1/GIP Agonist VK2735 | VANQUISH-1 and VANQUISH-2 Studies to Evaluate Subcutaneous VK2735 in Obese Adults with and without Type 2 Diabetes
SAN DIEGO, June 25, 2025 /PRNewswire/ -- Viking... ► Artikel lesen | |
INTELLIA THERAPEUTICS | 8,366 | +2,50 % | CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential? | ||
BIOCRYST PHARMACEUTICALS | 7,834 | -1,98 % | BioCryst Pharmaceuticals, Inc.: BioCryst Announces Sale of European ORLADEYO (berotralstat) Business to Neopharmed Gentili for up to $264 Million | -Neopharmed Gentili will pay BioCryst $250 million upfront for the European assets and rights related to ORLADEYO, and up to $14 million in future milestones-
-BioCryst plans to use proceeds to... ► Artikel lesen | |
TEMPUS AI | 56,44 | -0,67 % | Tempus AI's Data Business Keeps Scaling Up: Can the Growth Pace Last? | ||
SAREPTA THERAPEUTICS | 14,575 | -0,21 % | Did The FDA Make A Mistake? Sarepta's Elevidys Approval Under Scrutiny | ||
BIOMARIN PHARMACEUTICAL | 47,060 | -0,17 % | BioMarin Presents Long-term Efficacy And Safety Of Roctavian | WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical Inc. (BMRN) Tuesday announced new data underscoring the long-term efficacy and safety of Roctavian (valoctocogene roxaparvovec-rvox).The Phase... ► Artikel lesen |